Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®


INGELHEIM, Germany & INDIANAPOLIS, US–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.1 The findings were reported today at the American Diabetes Association’s 79th Scientific Sessions in San Francisco. The trial met its primary endpoint, defined as non-inferiority….